Perioperative Use of Angiotensin-Converting Enzyme Inhibitors


Since the introduction of the first angiotensin-converting enzyme inhibitor (ACEI), captopril, in 1981, ACEIs have become a mainstay of antihypertensive therapy. In addition to lowering blood pressure, there is overwhelming evidence that ACEIs (and angiotensin receptor blockers) provide end-organ protection independent of their blood pressure–lowering properties in diseases such as congestive heart failure, post– myocardial infarction (MI), diabetes mellitus, and renal insufficiency.1 It is an unresolved issue, however, whether ACEIs have a protective or deleterious effect on perioperative outcomes.2

Cite this paper

@inproceedings{Barodka2012PerioperativeUO, title={Perioperative Use of Angiotensin-Converting Enzyme Inhibitors}, author={Viachaslau Barodka and Daniel P Nyhan}, year={2012} }